OROTECH
ActiveSummary
OROTECH has been active since 2005 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €882,289 and a net result of €159,807. Equity is growing by ~11.4% per year across the filed fiscal years. Its solvency ranks better than 71% of 51 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.5% (low).
Checked score
Score 2024
Axes · tick = 2023
Profitability84▼-1
Solvency93▼-7
Growth78=
Track record100
Bankruptcy probability, 12 months
0.5%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €65,000 at 30 days acceptable
Liquidity ample (current ratio 1.53 against 7.93 in 2023; short-term debt: 32.3% and cash: 17.6% of total assets), and 32.3% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
67.7%
Return on assets
12.3%
Age of the figures
21 mo
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 23-06-2025, 38 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
not confirmed
2024
38 d early
2023
21 d late
2022
30 d late
2021
31 d late
2020
37 d early
2019
31 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 4 days before the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, abbreviated schema
Equity
€882,289▲ 20.9%
2023 · €730,066
Total assets
€1.3m▲ 64.1%
2023 · €794,282
Net result
€159,807▲ 55.8%
2023 · €102,592
Working capital
€224,558▼ 49.5%
2023 · €444,946
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Operating result-€26,564€121,615€60,137▼ 50.6%€104,354▲ 73.5%€162,764▲ 56.0%
Net result-€30,350within the sector's middle half€118,800within the sector's middle half€60,468within the sector's middle half▼ 49.1%€102,592within the sector's middle half▲ 69.7%€159,807above the sector's middle half▲ 55.8%
Equity€448,206within the sector's middle half▼ 6.3%€567,006within the sector's middle half▲ 26.5%€627,474within the sector's middle half▲ 10.7%€730,066within the sector's middle half▲ 16.3%€882,289within the sector's middle half▲ 20.9%
Total assets€547,240below the sector's middle half▼ 27.3%€715,970within the sector's middle half▲ 30.8%€725,567within the sector's middle half▲ 1.3%€794,282within the sector's middle half▲ 9.5%€1.3mwithin the sector's middle half▲ 64.1%
Debt€99,033▼ 63.8%€148,964▲ 50.4%€98,093▼ 34.1%€64,216▼ 34.5%€420,919▲ 555%
Working capital€151,496within the sector's middle half▲ 37.6%€288,818within the sector's middle half▲ 90.6%€398,709within the sector's middle half▲ 38.0%€444,946within the sector's middle half▲ 11.6%€224,558within the sector's middle half▼ 49.5%
Solvency81.9%above the sector's middle half▲ 18.3pp79.2%above the sector's middle half▼ 2.7pp86.5%above the sector's middle half▲ 7.3pp91.9%above the sector's middle half▲ 5.4pp67.7%within the sector's middle half▼ 24.2pp
Current ratio3.29above the sector's middle half▲ 1.842.94above the sector's middle half▼ 0.355.06above the sector's middle half▲ 2.137.93above the sector's middle half▲ 2.861.53within the sector's middle half▼ 6.40
Return on assets (ROA)-5.5%below the sector's middle half▼ 8.1pp16.6%above the sector's middle half▲ 22.1pp8.3%within the sector's middle half▼ 8.3pp12.9%within the sector's middle half▲ 4.6pp12.3%above the sector's middle half▼ 0.7pp
Staff (FTE)1.6=1.6=1.6below the sector's middle half=1.6within the sector's middle half=1.6within the sector's middle half=
above
within
below
the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2022 the operating result has climbed two years in a row; 2024 is 56% above 2023 and is the highest result in the available series.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €1.3m
Fixed assets
€657,731 ▲ 131%
Current assets
€645,477 ▲ 26.8%
Equity and liabilities €1.3m
Equity
€882,289 ▲ 20.9%
Debt
€420,919 ▲ 555%
Debt's share of the balance-sheet total rises from 8.1% to 32.3%. Equity and debt are higher.
Key figures and ratios
EBITDA
€251,286▲
2023 · €197,565
Cash flow
€248,330▲
2023 · €195,803
Debt to equity
0.48▲
2023 · 0.09
ROE
18.1%▲
2023 · 14.1%
Interest coverage
1543.62▲
2023 · 546.00
Debt ≤ 1 year
€420,919▲
2023 · €64,216
Income taxes
€3,252▲
2023 · €1,407
Staff costs
€106,982▲
2023 · €100,029
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 31,349 companies that looked in July 2024 the way this one looks now, 0.4% went bankrupt within 24 months and 93% are still going.
- Micro
- 20 years or older
- solvency 30% or more
- a profit of 5% of the balance sheet or more
0.4%
went bankrupt
5.9%
stopped otherwise
93%
still going
A further 0.2% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.5% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,662 companies of July 2024 its group's bankruptcy share. Expected: 1.5%; actually bankrupt within 24 months: 1.6%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.4% |
| 3 | 0.5% | 0.5% |
| 4 | 0.6% | 0.7% |
| 5 | 0.8% | 0.9% |
| 6 | 1.2% | 1.3% |
| 7 | 1.5% | 1.7% |
| 8 | 1.7% | 1.7% |
| 9 | 2.7% | 2.8% |
| 10 | 5.3% | 5.7% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 75% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 31,349 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | €104,264 | €93,369 | €100,029 | €106,982 | ▲ 7.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €77,391 | €82,958 | €86,912 | €93,211 | €88,523 | ▼ 5.0% |
| Other operating charges640/8 | - | €8,242 | €9,138 | €9,612 | €6,357 | ▼ 33.9% |
| Non-recurring operating charges66A | - | - | - | €4,707 | - | - |
| Gross operating margin9900 | €164,957 | €317,079 | €249,556 | €311,913 | €364,624 | ▲ 16.9% |
| Operating profit (loss)9901 | -€26,564 | €121,615 | €60,137 | €104,354 | €162,764 | ▲ 56.0% |
| Financial income75/76B | - | €742 | €2,924 | €6 | €459 | ▲ 7,343% |
| Recurring financial income75 | €564 | €742 | €2,924 | €6 | €459 | ▲ 7,343% |
| Financial charges65/66B | - | €2,213 | €1,180 | €362 | €163 | ▼ 55.0% |
| Recurring financial charges65 | €2,870 | €2,213 | €1,180 | €362 | €163 | ▼ 55.0% |
| Profit (loss) for the period before taxes9903 | -€28,870 | €120,144 | €61,882 | €103,998 | €163,059 | ▲ 56.8% |
| Income taxes67/77 | €1,480 | €1,344 | €1,414 | €1,407 | €3,252 | ▲ 131% |
| Profit (loss) for the period9904 | -€30,350 | €118,800 | €60,468 | €102,592 | €159,807 | ▲ 55.8% |
| Profit (loss) for the period to be appropriated9905 | -€30,350 | €118,800 | €60,468 | €102,592 | €159,807 | ▲ 55.8% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €547,240 | €715,970 | €725,567 | €794,282 | €1.3m | ▲ 64.1% |
| Fixed assets21/28 | €329,661 | €278,188 | €228,765 | €285,119 | €657,731 | ▲ 131% |
| Tangible fixed assets22/27 | €329,661 | €278,188 | €228,765 | €285,119 | €657,731 | ▲ 131% |
| Land and buildings22 | - | €216,329 | €173,722 | €165,874 | €558,313 | ▲ 237% |
| Plant, machinery and equipment23 | - | €44,379 | €42,967 | €41,555 | €41,088 | ▼ 1.1% |
| Furniture and vehicles24 | - | €17,479 | €12,076 | €77,690 | €58,330 | ▼ 24.9% |
| Current assets29/58 | €217,579 | €437,782 | €496,802 | €509,162 | €645,477 | ▲ 26.8% |
| Amounts receivable within one year40/41 | €34,442 | €364,592 | €337,498 | €434,363 | €404,471 | ▼ 6.9% |
| Trade receivables40 | - | €346,532 | €330,203 | €398,575 | €401,933 | ▲ 0.8% |
| Other amounts receivable41 | - | €18,059 | €7,295 | €35,788 | €2,538 | ▼ 92.9% |
| Current investments50/53 | €1,500 | €1,500 | €1,500 | - | - | - |
| Cash at bank and in hand54/58 | €180,219 | €68,160 | €156,320 | €61,839 | €229,879 | ▲ 272% |
| Deferred charges and accrued income490/1 | - | €3,531 | €1,484 | €12,960 | €11,126 | ▼ 14.1% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €547,240 | €715,970 | €725,567 | €794,282 | €1.3m | ▲ 64.1% |
| Equity10/15 | €448,206 | €567,006 | €627,474 | €730,066 | €882,289 | ▲ 20.9% |
| Contributions10/11 | €724,200 | €724,200 | €724,200 | €724,200 | €724,200 | = |
| Capital10 | - | €724,200 | €724,200 | €724,200 | €724,200 | = |
| Issued capital100 | - | €724,200 | €724,200 | €724,200 | €724,200 | = |
| Reserves13 | €12,000 | €12,000 | €12,000 | €12,000 | €158,089 | ▲ 1,217% |
| Non-distributable reserves130/1 | - | €12,000 | €12,000 | €12,000 | €20,100 | ▲ 67.5% |
| Legal reserve130 | - | €12,000 | €12,000 | €12,000 | €20,100 | ▲ 67.5% |
| Distributable reserves133 | - | - | - | - | €137,989 | - |
| Profit (loss) carried forward14 | -€287,994 | -€169,194 | -€108,726 | -€6,134 | - | - |
| Amounts payable17/49 | €99,033 | €148,964 | €98,093 | €64,216 | €420,919 | ▲ 555% |
| Amounts payable within one year42/48 | €66,083 | €148,964 | €98,093 | €64,216 | €420,919 | ▲ 555% |
| Trade debts44 | €31,260 | €31,261 | €70,045 | €45,717 | €27,176 | ▼ 40.6% |
| Suppliers440/4 | - | €31,261 | €70,045 | €45,717 | €27,176 | ▼ 40.6% |
| Taxes, remuneration and social security45 | - | €57,703 | €28,048 | €18,498 | €67,458 | ▲ 265% |
| Taxes450/3 | - | €45,562 | €16,560 | €6,293 | €55,502 | ▲ 782% |
| Remuneration and social security454/9 | - | €12,141 | €11,488 | €12,205 | €11,956 | ▼ 2.0% |
| Other amounts payable47/48 | - | €60,000 | - | - | €326,286 | - |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€30,350 | €118,800 | €60,468 | €102,592 | €159,807 | ▲ 55.8% |
| + Depreciation and write-downs630 | €77,391 | €82,958 | €86,912 | €93,211 | €88,523 | ▼ 5.0% |
| Operating cash flow (approximation) | €47,041 | €201,758 | €147,380 | €195,803 | €248,330 | ▲ 26.8% |
| Investment in fixed assets (approximation) | - | -€31,485 | -€37,489 | -€149,565 | -€461,134 | ▼ 208% |
| Change in cash | - | -€112,059 | €88,160 | -€94,481 | €168,040 | ▲ 278% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
23-06
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Highest result since 2018net €159,807 ▲55.8%
Operating result €162,764, net result €159,807, both a record.
21-08
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 21 days late
2023
30-08
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 30 days late
2022
31-08
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema · 31 days late
2021
31-12
Financial
Back to profitnet €118,800
Net result €118,800 after one loss-making year.
31-12
Financial
Equity above €500,000Eq €567,006 ▲26.5%
Equity rises from €448,206 to €567,006.
24-06
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
31-12
Financial
Weakest financial yearnet -€30,350
Net result drops to -€30,350, the lowest in the series; recovery starts the following year.
31-12
Financial
Liquidity doublescurrent ratio 3.29
Current ratio from 1.46 to 3.29; short-term debt falls from €240,815 to €66,083.
30-06
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2019
24-06
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
Show earlier events
2018
29-06
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
03-07
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
2016
21-06
NBB filing
Annual accounts filed
fiscal year 2015 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 9 acts read
About the unread acts
We know of 9 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
9 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Temse · 2 establishment units since 2005
Ground area
1,544 m²
Building footprint
369 m²
Volume, LiDAR
4,453 m³
2 parcels, Flanders · tallest building 16.8 m, ±5 floors. Linked by address, not a title deed.
2 establishment units
OROTECH
since 20052.217.815.027
OROTECH
since 20132.217.815.522
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 46302D0284/00T000 | Flanders | 1,352 m² | 1 · 274 m² | 16.8 m · 5 fl. |
| 44808H0459/00B002indicative | Flanders | 192 m² | 1 · 95 m² | 10.9 m · 1 fl. |
Linked by address, not proof of ownership
Good to know
1 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Owners and holdings
1 ownerChain of control
- ORLAY
- OROTECH
Highest known parent: ORLAY. The sources do not say who stands above it.
Owners 1
- ORLAYparentSourceaccounts ORLAY 2024100%
Holdings 0
No holding stated in the accounts, acts or LEI register we read.
According to the annual accounts of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
No current directors or connected companies found in the register.
Similar companies · same sector, comparable size
PHENIX PROPERTY
BE 0413.676.987
Hoogstraten · Eq €934,134
Axo Industry International
BE 0859.791.271
Wavre · Eq €940,443
BIVIT
BE 0439.165.025
Wevelgem · Eq €780,157
SIMABS
BE 0732.709.096
Diepenbeek · Eq €1.0m
San'Up
BE 0693.818.729
Aywaille · Eq €608,894
Of 148 companies in sector 21201 we hold annual accounts for 118. 60 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPublic limited company
Founded29-11-2005
Fiscal year end31-12
Activities, NACEBEL 2025
21201Manufacture of basic pharmaceutical products and pharmaceutical preparations
72109Other research and development on natural sciences
E-invoicing
Reachable via Peppol
Peppol ID
0208:0877916118
Registered
27-03-2026
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 28 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.